Research in Your Backyard

Developing Cures, Creating Jobs



PHARMACEUTICAL CLINICAL TRIALS IN OHIO

Dots show locations of clinical trials in the state.

PhRMA

Executive Summary

Clinical Trials in Ohio

- Biopharmaceutical research companies are conducting or have conducted nearly 5,000 clinical trials of new medicines in collaboration with the state's clinical research centers, university medical schools and hospitals (1999 to present).

- Of the nearly 5,000 clinical trials, 2,494 target or have targeted the nation's six most debilitating chronic diseases—**asthma, cancer, diabetes, heart disease, mental illnesses** and **stroke**.

Economic Benefits of Clinical Trials in Ohio

- Biopharmaceutical research companies have been an important source of jobs, tax revenue and research spending in Ohio.

- A study by Archstone Consulting found that in 2008 the industry supported more than 84,000 jobs throughout the state.

- Employees working directly for the companies were paid $847.6 million, leading to more than $24 million in state taxes and more than $193 million in federal taxation.

- Biopharmaceutical research firms that year also invested $734.6 million in research and development and supported $16.2 billion in products and services.

- Company employees in Ohio include life sciences researchers, management executives, office and administrative support workers, engineers, architects, computer and math experts and sales representatives

About Clinical Trials

- In the development of new medicines, clinical trials are conducted to prove therapeutic safety and effectiveness and compile the evidence needed for the Food and Drug Administration (FDA) to approve treatments.

Clinical Trials in Ohio since 1999—Completed and Active

All Clinical Trials	Six Major Chronic Diseases
4,972	2,494

Source: www.clinicaltrials.gov
Note: Search criteria = Ohio, Phase I, II, III; industry only.
Search performed 4/26/2012.

- Clinical tests of new drugs are conducted in three phases and account for an average of seven of the 10 to 15 years it takes to take a new drug from development to patients.

- Clinical trials for a given drug or treatment involve thousands of volunteer patient participants, and the generation of tens of thousands of pages of technical and scientific data.

- Clinical trials are responsible for 45 to 75 percent of the $1.2 billion average cost of developing one new cutting-edge biotechnology medicine.

- Biopharmaceutical companies frequently hire local research institutions to conduct the tests.

- For patients, the trials offer another potential therapeutic option. Clinical tests may provide a new avenue of care for some chronic disease sufferers who are still searching for the medicines that are best for them.

- All clinical trials must be reviewed and approved by an Institutional Review Board (IRB), an independent committee of physicians, statisticians, local community advocates and others to ensure a trial is ethically conducted and patient rights are protected.

- Clinical trial progress reports must be submitted at least annually to the FDA and the IRB.

- All facilities that conduct or support biomedical research involving patients must comply with federal regulations and have an IRB.

Clinical Trials and Chronic Diseases

- Chronic diseases pose the greatest threats to our nation's health and our ability to treat and prevent medical conditions.

Clinical Trials for Top Chronic Diseases

Chronic Disease	All Clinical Trials	Clinical Trials Still Recruiting
Asthma	96	20
Cancer	1,183	262
Diabetes	368	53
Heart Disease	252	44
Mental Illness	552	86
Stroke	43	10
Total	**2,494**	**475**

Source: www.clinicaltrials.gov
Note: Search criteria = Ohio, Phase I, II, III; industry only. Search performed 4/26/2012. Some clinical trials appear in more than one disease category.

Clinical Trials in Ohio Communities

Location	Asthma	Cancer	Diabetes	Heart Disease	Mental Illness	Stroke
Akron	--	11	9	7	3	3
Beachwood	1	--	2	--	13	--
Canton	3	38	3	6	15	1
Centerville	1	--	2	2	--	2
Cincinnati	16	81	24	24	40	6
Cleveland	2	96	16	25	19	8
Columbus	5	103	18	21	16	7
Dayton	2	13	10	8	24	2
Fairfield	--	2	--	5	--	1
Garfield Heights	--	--	--	2	3	1
Kettering	--	10	7	6	--	2
Mansfield	--	1	--	2	--	1
Marion	1	--	7	5	--	3
Maumee	--	1	6	1	--	1
Mentor	1	--	5	2	--	1
Middletown	--	29	--	1	--	--
Perrysburg	--	--	4	1	--	1
Sandusky	--	6	--	3	--	1
Springfield	--	--	2	3	--	1
Toledo	3	12	8	10	12	4
Westlake	--	2	1	2	--	1
Willoughby Hills	--	1	2	1	--	1
Youngstown	--	1	--	1	--	1
Zanesville	--	--	3	4	--	2

Source: www.clinicaltrials.gov
Note: Search criteria = Ohio, Phase I, II, II; industry only. Search performed 4/26/2012. See Appendix for detailed information about these clinical trials. Disease columns will not match totals in the Appendix because some clinical trials are recruiting in more than one city.

- According to the Centers for Disease Control and Prevention, today, in the United States:
    - Patients with chronic diseases **account for 75 cents of every dollar** spent on health care.
    - Chronic diseases are the **leading cause of death and disability.**
    - Chronic diseases are a **leading driver of rising health care costs** with expenses totaling billions of dollars every year.
- Biopharmaceutical research companies are developing new medicines to help treat those conditions that are taking an unprecedented toll on American lives, and many of these medicines are being tested today in clinical trials throughout Ohio.
- Since 1999, biopharmaceutical research companies are sponsoring or have sponsored 2,494 clinical trials of potential new medicines in Ohio alone for **asthma, cancer, heart disease, stroke, diabetes** and **mental illnesses.** Of these trials, 475 are either not yet recruiting or are just now seeking Ohio patients.
- Many of the state's clinical tests involve collaborations with such respected local institutions as the **Cleveland Clinic Foundation** and the **University Hospitals of Cleveland at Case Western Reserve University** in Cleveland, the **Ohio State University Medical Center** in Columbus, and the **Linder Research Center at Christ Hospital** and the **University of Cincinnati Medical Center** in Cincinnati.
- Many of the medicines being clinically tested here are new-generation biotechnology treatments.

Clinical Trials in Ohio

Clinical tests of new medicines are a vitally important part of the drug development and approval process—they account for 45 to 75 percent of the $1.2 billion average cost of developing a new drug and are conducted to determine the safety and effectiveness of that treatment in patients.

Some trials are also conducted to compare existing treatments and some are done to learn if a drug is appropriate for a different patient population, such as children. Still others are conducted to find ways to make existing approved drugs more effective and easier to use with fewer side effects.

It's essential that trials be conducted properly so that clinicians and drug reviewers can develop accurate assessments of the efficacy and safety of medicines used by patients. The FDA is a vigilant regulatory agency and its pharmaceutical review officers are effective in detecting flawed information.

Questionable or confusing data can lead to lengthy delays in product approval or outright FDA rejection of a new drug.

Biopharmaceutical research companies are looking for the best physicians and research institutions to meticulously help design and conduct their clinical trials to determine whether a medicine is safe and effective. Side effects must be painstakingly documented and a determination made as to whether they occur too often and are dangerous.

Clinical tests involve three phases and thousands of volunteer patients and are often conducted at multiple sites around the country. In Ohio, biopharmaceutical companies have the opportunity of conducting trials at the states' well-respected university medical schools, comprehensive cancer centers, and clinical trial research centers. According to *U.S. News and World Report*, **Case Western Reserve University** ranked 22nd, **The Ohio State University** ranked 38th, and the **University of Cincinnati** ranked 42nd among last year's top 100 research-oriented medical schools in the United States. Other ranked medical schools included Northeast Ohio Medical University in Rootstown, the University of Toledo, and Wright State University in Dayton.

Clinical Trials for Top Chronic Diseases

Chronic Disease	All Clinical Trials	Clinical Trials Still Recruiting
Asthma	96	20
Cancer	1,183	262
Diabetes	368	53
Heart Disease	252	44
Mental Illness	552	86
Stroke	43	10
Total	**2,494**	**475**

Source: www.clinicaltrials.gov
Note: Search criteria = Ohio, Phase I, II, III; industry only. Search performed 4/26/2012. Some clinical trials appear in more than one disease category.

Asthma is a debilitating condition for more than 24 million Americans, including 7 million children under the age of 18. The toll is also severe in Ohio—in 2010, an estimated 1.2 million adults and 412,000 children suffered from asthma, according to the Ohio Department of Health.

Currently, 20 clinical trials of new asthma medicines are recruiting patients in Ohio. Trials are being conducted at the **Bernstein Clinical Research Center** and the **Cincinnati Children's Hospital Medical Center** in Cincinnati, **Dayton Clinical Research** in Dayton, and **Toledo Center for Clinical Research** in Sylvania.

Cancer, the second leading cause of death in the United States, now afflicts nearly 12 million Americans, according to the National Cancer Institute. In Ohio, more than 66,000 new cancer cases will be diagnosed this year and 25,030 victims in the state will die, according to the American Cancer Society.

Currently, 262 clinical trials of new cancer medicines are recruiting patients in Ohio. Biopharmaceutical companies are collaborating on the tests with such prominent institutions as the **Taussig Cancer Institute at Cleveland Clinic** and the **Seidman Cancer Center at University Hospitals** in Cleveland. Other trials are being conducted at the **Arthur G. James Cancer Hospital** and **Richard J. Solove Research Institute at Ohio State University** in Columbus, the **Mercy Cancer Center at Mercy St. Anne Hospital** in Toledo, the **Gabrail Cancer Center** in Canton, the **Mercy Cancer Center** in Elyria, and the **University of Cincinnati Cancer Institute** in Cincinnati.

Diabetes affects more than 25 million Americans—about 8 percent of the U.S. population—and nearly one-third are unaware they have the disease. In Ohio, an estimated 889,381 adults have been diagnosed with diabetes, according to the Ohio Department of Health.

Currently, 53 diabetes clinical tests are seeking patients in Ohio. The trials are being conducted at the **Akron Children's Hospital** in Akron, **Case Western Reserve University** in Cleveland, the **Ohio University College of Osteopathic Medicine** in Athens, the **University of Toledo** in Toledo, and **The Carl and Edyth Linder Center for Research and Education at Christ Hospital** in Cincinnati.

Heart disease and stroke are the first and fourth leading disease causes of death in the United States and in Ohio. According to the American Heart Association, more than 82 million Americans are affected by these diseases. In Ohio, in 2009, more than 25,800 residents died from some form of heart disease and more than 5,500 died from a stroke, according to the Ohio Department of Health.

Currently, 44 heart disease and 10 stroke clinical tests are seeking patients in Ohio. Trials are being conducted at the **Cardiovascular Research Center** in Toledo, **Cincinnati Children's Hospital Medical Center** and the **University of Cincinnati Medical Center** in Cincinnati, the **Cardiology Department at The Cleveland Clinic** and the **Harrington-McLaughlin Heart and Vascular Institute** in Cleveland, the **Richard M. Ross Heart Hospital at The Ohio State University** in Columbus, the **North Ohio Heart Center** in Elyria, and the **Kettering Medical Center** in Kettering.

Mental illness affects nearly 60 million Americans suffering from some form of the disease—from anxiety to depression to schizophrenia to eating disorders. In Ohio, nearly 418,000 adults live with serious mental illness and about 124,000 children live with serious mental health conditions, according to the National Alliance on Mental Illness.

Currently, 86 clinical trials on mental illness are recruiting patients in Ohio. Trials are taking place at **The Ohio State University Nisonger Center** in Columbus, the **Department of Psychiatry and Behavioral Neuroscience at the University of Cincinnati** and the **Lindner Center for HOPE** in Cincinnati, the **Akron Children's Hospital** in Akron, the **Neurology and Neuroscience Center of Ohio** in Toledo, the **Ohio Sleep Medicine Institute** in Dublin, and the **University Hospitals of Cleveland Case Medical Center** and the **VA Medical Center** in Cleveland.

*Physicians and patients can find out about clinical trials being conducted across the state in collaboration with local institutions by accessing **www.clinicaltrials.gov,** a database sponsored by the National Institutes of Health. Information on medicines in development is also available on **www.phrma.org**, the website of the Pharmaceutical Research and Manufacturers of America (PhRMA).*

What is the Clinical Trial Experience?

Clinical trials are research studies which grant participants early access to new drugs, treatments, and therapies that are being developed to help combat chronic, serious and life threatening diseases. By volunteering for a clinical trial, patients take an active role in their healthcare by helping researchers test new medical treatments, and helping to find better ways of using existing treatments so they will be more effective, easier to use, and result in fewer or more tolerable side effects. In Ohio alone, thousands of clinical trials are taking place to study diseases like asthma, cancer, diabetes, heart disease, mental illness, and stroke.

Phases of Clinical Trials

There are three phases of testing used to evaluate new drugs and treatments:

Phase I—This phase is designed to test the safety of a new drug or treatment. Researchers test the drug on a small group of people (20-80) and evaluate safety aspects of the drug, such as safe dosage range, the best way of administering the treatment (pill form vs. a shot for example), and identifying what, if any, side effects present themselves.

Phase II—This phase is designed to test efficacy and to further measure safety. The treatment is given to a larger group of people (100-300) to make sure the treatment works correctly, and to try to identify any less-common side effects, which may appear when more people are tested. This phase is usually placebo-controlled and double-blinded, meaning neither the patient nor the doctor knows whether the patient is getting the placebo or the real treatment.

Phase III—This phase is meant to confirm efficacy and safety information, monitor known side effects, and compare the experimental treatment to commonly used ones to see which work better. A large group (1000-3000) receives this treatment, and like Phase II, it is usually placebo-controlled and double-blinded.

Learning About and Accessing Clinical Trials

There are several ways patients can access information about clinical trials. Healthcare providers are aware of clinical trials being conducted at hospitals, universities, and other leading healthcare facilities, and can be valuable sources of information for patients looking to participate. Patients can also turn to hospitals' and universities' websites to see what studies are being conducted in their area, and what the eligibility criteria are for each trial. More information about clinical trials and volunteering can be found at ***http://centerwatch.com/***, a PhRMA-recommended website.

What to Expect

Treatments for clinical trials usually take place in a doctor's office. Patients may need to devote more time to doctor's visits and physical exams than they would normally. They may also have additional responsibilities, like keeping a daily log of their health. All prospective participants must sign an informed consent document saying they understand the clinical trial is research, and that they can leave the trial at any time. Once they have consulted with their healthcare providers, patients can reach out via phone or email to express interest in participating, at which point a pre-screening interview will take place. If the patient matches the trial's criteria, they will then be able to enroll in the study.

Patient Expenses

Patients should always ask during their pre-screening interviews what it will cost them to participate in a clinical trial. Sponsors for clinical trials will usually pay for all research-related costs and any additional testing or doctor's visits the trial requires. Patients or their insurance companies may be asked to pay for any routine treatments that they would normally undergo for their disease. However, some health plans do not pay for these costs once a patient joins the trial. Patients should be sure to check with the clinic conducting the trial to find out if they or their insurances companies will be charged with any fees, and should make sure their insurance companies will cover the costs of routine exams if they join a trial.

Non-local patients should be sure to look into the sponsoring clinic's policy on patient living arrangements. The National Cancer Institute, for example, makes patients responsible for their own travel costs for the initial screening visits. Once a patient is enrolled, the Institute will pay for transportation costs for all subsequent trial-related visits. These patients will receive a small per diem for food and lodging. The policy will differ from clinic to clinic.

New Generation Medicines in Development

Many of the medicines being tested in Ohio are cutting-edge biotechnology drugs.

America's biopharmaceutical research companies are using biotechnology to develop hundreds of medicines and vaccines today. And Ohio is one of the states where extensive new-generation research and development work is being done.

Through biotechnology, new ways are being developed to not only more effectively treat disease, but also to predict, preempt, and prevent it.

Biotechnology medicines are developed through biological processes using living cells or organisms, rather than traditional chemical synthesis, the mainstay of pharmaceutical development for decades.

Such novel treatments use a variety of new approaches to treat disease. For example, a monoclonal antibody is a laboratory-made version of the naturally occurring immune system protein that binds to and neutralizes foreign invaders. Interferons are proteins that interfere with the ability of a cell to reproduce.

Antisense drugs, meanwhile, are medicines that interfere with the communication process that tells a cell to produce an unwanted protein. In addition, nanotechnology is being used in biotechnology research to provide drug-delivery systems, new treatments, and diagnostics.

Many of the medicines in clinical testing at Ohio medical schools and research centers feature these technologies. For example:

- A genetically-modified virus-based vaccine to treat melanoma.
- A monoclonal antibody for the treatment of cancer.
- An antisense medicine for the treatment of cancer.
- A recombinant fusion protein to treat age-related macular degeneration and diabetic macular edema.
- A monoclonal antibody in the pipeline targets lupus and various types of cancer.
- A therapeutic vaccine, designed to jump-start the immune system to fight disease, is in development for lung cancer and melanoma.

These are only a portion of the examples of new ways the nation's biopharmaceutical companies and Ohio research institutions are working together to attack disease. The biotechnology medicines and vaccines in development promise to push the frontiers of science and potentially bring more and better treatments to patients.

Conclusion

Biopharmaceutical companies' close collaboration with clinicians and research institutions in Ohio benefits patients, the state's economy, and the advancement of science and patient care. Clinical trial work is good business for the state's medical schools and clinical research centers and the medicines being tested are often cutting-edge cell and protein treatments with the potential to be safer and more effective than older chemical compound drugs.

What's more, Ohioans contemplating participation in clinical trials, in consultation with their doctors, have a wide range of choices—nearly 500 tests of new medicines for the six most debilitating chronic diseases in America are underway in communities large and small all over the state and they need patient volunteers.

The Drug Discovery, Development and Approval Process

It takes 10-15 years on average for an experimental drug to travel from the lab to U.S. patients. Only five in 5,000 compounds that enter preclinical testing make it to human testing. One of these five tested in people is approved.

Clinical Trials

	Discovery/ Preclinical Testing	File IND at FDA	Phase I	Phase II	Phase III	File NDA/BLA at FDA	FDA	Phase IV
Years	**6.5**		**1.5**	**2**	**3.5**		**1.5**	
Test Population	Laboratory and animal studies		20 to 100 healthy volunteers	100 to 500 patient volunteers	1,000 to 5,000 patient volunteers		Review process/ approval	Additional post-marketing testing required by FDA
Purpose	Assess safety, biological activity and formulations		Determine safety and dosage	Evaluate effective-ness, look for side effects	Confirm effectiveness, monitor adverse reactions from long-term use			
Success Rate	5,000 compounds evaluated		5 enter trials				1 approved	

The Drug Development and Approval Process

The U.S. system of new drug approvals is perhaps the most rigorous in the world.

It takes 10-15 years, on average, for an experimental drug to travel from lab to U.S. patients, according to the Tufts Center for the Study of Drug Development. Only five in 5,000 compounds that enter preclinical testing make it to human testing. And only one of those five is approved for sale.

On average, it costs a company $1.2 billion, including the cost of failures, to get one new medicine from the laboratory to U.S. patients, according to a 2007 study by the Tufts Center for the Study of Drug Development.

Once a new compound has been identified in the laboratory, medicines are usually developed as follows:

Preclinical Testing. A pharmaceutical company conducts laboratory and animal studies to show biological activity of the compound against the targeted disease, and the compound is evaluated for safety.

Investigational New Drug Application (IND). After completing preclinical testing, a company files an IND with the U.S. Food and Drug Administration (FDA) to begin to test the drug in people. The IND shows results of previous experiments; how, where and by whom the new studies will be conducted; the chemical structure of the compound; how it is thought to work in the body; any toxic effects found in the animal studies; and how the compound is manufactured. All clinical trials must be reviewed and approved by the Institutional Review Board (IRB) where the trials will be conducted. Progress reports on clinical trials must be submitted at least annually to FDA and the IRB.

Clinical Trials, Phase I. These tests usually involve about 20 to 100 healthy volunteers. The tests study a drug's safety profile, including the safe dosage range. The studies also determine how a drug is absorbed, distributed, metabolized, and excreted as well as the duration of its action.

Clinical Trials, Phase II. In this phase, controlled trials of approximately 100 to 500 volunteer patients (people with the disease) assess a drug's effectiveness and determine the early side effect profile.

Clinical Trials, Phase III. This phase usually involves 1,000 to 5,000 patients in clinics and hospitals. Physicians monitor patients closely to confirm efficacy and identify adverse events.

New Drug Application (NDA)/Biologic License Application (BLA). Following the completion of all three phases of clinical trials, a company analyzes all of the data and files an NDA or BLA with FDA if the data successfully demonstrate both safety and effectiveness. The applications contain all of the scientific information that the company has gathered. Applications typically run 100,000 pages or more.

Approval. Once FDA approves an NDA or BLA, the new medicine becomes available for physicians to prescribe. A company must continue to submit periodic reports to FDA, including any cases of adverse reactions and appropriate quality-control records. For some medicines, FDA requires additional trials (Phase IV) to evaluate long-term effects.

Discovering and developing safe and effective new medicines is a long, difficult, and expensive process. PhRMA member companies invested an estimated $49.5 billion in research and development in 2011.

The Good News– Many Clinical Trials are Still Recruiting

There are 475 clinical trials recruiting in Ohio. These trials target the top six chronic diseases and other debilitating diseases affecting Americans and Ohioans.

Clinical Trials in Ohio Communities

Location	Asthma	Cancer	Diabetes	Heart Disease	Mental Illness	Stroke
Akron	–	11	9	7	3	3
Beachwood	1	–	2	–	13	--
Canton	3	38	3	6	15	1
Centerville	1	–	2	2	–	2
Cincinnati	16	81	24	24	40	6
Cleveland	2	96	16	25	19	8
Columbus	5	103	18	21	16	7
Dayton	2	13	10	8	24	2
Fairfield	--	2	–	5	–	1
Garfield Heights	--	–	–	2	3	1
Kettering	--	10	7	6	–	2
Mansfield	--	1	--	2	–	1
Marion	1	–	7	5	–	3
Maumee	--	1	6	1	–	1
Mentor	1	–	5	2	–	1
Middletown	--	29	–	1	–	--
Perrysburg	--	–	4	1	–	1
Sandusky	--	6	–	3	–	1
Springfield	--	–	2	3	–	1
Toledo	3	12	8	10	12	4
Westlake	--	2	1	2	–	1
Willoughby Hills	--	1	2	1	–	1
Youngstown	--	1	–	1	–	1
Zanesville	--	–	3	4	–	2

Source: www.clinicaltrials.gov

Note: Search criteria = Ohio, Phase I, II, II; industry only. Search performed 4/26/2012. See Appendix for detailed information about these clinical trials. Disease columns will not match totals in the Appendix because some clinical trials are recruiting in more than one city.

The Good News–Many Clinical Trials are Still Recruiting

(continued)

Asthma—Leading Institutions Conducting Clinical Trials

Bernstein Clinical Research Center, Cincinnati
Cincinnati Children's Hospital Medical Center, Cincinnati
Dayton Clinical Research, Dayton
New Horizons Clinical Research, Cincinnati
Optimed Research, Columbus
Toledo Center for Clinical Research, Sylvania

Cancer—Leading Institutions Conducting Clinical Trials

Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University, Columbus
Barberton Citizens Hospital Cancer Center, Barberton
The Christ Hospital, Cincinnati
Cincinnati Children's Hospital Medical Center, Cincinnati
Cleveland Clinic Hospital, Cleveland
Columbus Urology Research, Columbus
Dayton Clinical Oncology Program, Dayton
Forum Health Cancer Care Center, Youngstown
Gabrail Cancer Center Research, Canton
Greater Cincinnati OB/GYN, Cincinnati
Hematology Oncology Consultants, Columbus
Hickman Cancer Center at Flower Hospital, Sylvania
Jean and Milton Cooper Cancer Center, Akron
Kettering Medical Center Health Network, Kettering
Mercy Cancer Center, Elyria
Mercy Cancer Center at Mercy St. Anne Hospital, Toledo
Mercy St. Vincent Medical Center, Toledo
Miami Valley Hospital, Kettering
Mid-Ohio Oncology/Hematology, Columbus
Nationwide Children's Hospital, Columbus
North Coast Cancer Care, Sandusky
Ohio Cancer Specialists, Mansfield
The Ohio State University Medical Center, Columbus
Oncology Hematology Care, Cincinnati
ProMedica Health System, Toledo
Riverside Methodist Hospital, Columbus
Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center at Cleveland Clinic, Cleveland
Signal Point Clinical Research Center, Middletown
Summa Akron City Hospital, Akron
The Taussig Cancer Institute at Cleveland Clinic, Cleveland
Toledo Clinic Cancer Center, Toledo
Toledo Community Hospital Oncology Program, Toledo
Toledo Hospital, Toledo
Triology Cancer Care, Wooster
TriState Urologic Services, Cincinnati
University Hospitals of Cleveland at Case Western Reserve University, Cleveland
University Hospitals Seidman Cancer Center, Cleveland
University of Cincinnati Cancer Institute, Cincinnati
University of Cincinnati Physicians, Cincinnati
University Pointe, West Chester

Diabetes—Leading Institutions Conducting Clinical Trials

Akron Children's Hospital, Akron
Case Western Reserve University, Cleveland
Cleveland Clinic, Cleveland
Cleveland Clinic Foundation, Cleveland
Clinical Inquest Center, Beavercreek
Clinical Research Limited, Canton
Clinical Research Source, Perrysburg
Community Research, Cincinnati
Family Practice Center of Wadsworth, Wadsworth
MedPace Clinical Pharmacology, Cincinnati
Metrohealth Medical Center, Cleveland
Nationwide Children's Hospital, Columbus
Neurology and Neuroscience Center of Ohio, Toledo
Ohio College of Podiatric Medicine, Independence
The Ohio State University Comprehensive Wound Center, Columbus
The Ohio State University, Columbus
Ohio University College of Osteopathic Medicine, Athens
Providence Health Partners, Dayton
Retina Associates of Cleveland, Beachwood
Sterling Research Group, Cincinnati

The Linder Research Center at Christ Hospital, Cincinnati
University of Cincinnati, Cincinnati
University of Toledo, Toledo
Wells Institute for Health Awareness, Kettering
Your Diabetes Endocrine Nutrition Group, Mentor

Heart Disease and Stroke—Leading Institutions Conducting Clinical Trials

Cardiology Associates of Southeast Ohio, Zanesville
Cardiovascular Associates of Cleveland, Mayfield Heights
Cardiovascular Research Center, Toledo
Carl and Edyth Linder Center for Research and Education at The Christ Hospital, Cincinnati
Cincinnati Children's Hospital Medical Center, Cincinnati
Cleveland Clinic Foundation, Cardiology Department, Cleveland
Good Samaritan Hospital, Dayton
Harrington-McLaughlin Heart and Vascular Institute, University Hospitals of Cleveland, Cleveland
Kettering Medical Center, Kettering
Mercy Hospital, Fairfield
Metrohealth Medical Center, Cleveland
North Ohio Heart Center-North Ohio Research, Elyria
Northeast Ohio Cardiovascular, Akron
Ohio Health Research Institute, Columbus
Richard M. Ross Heart Hospital at The Ohio State University Medical Center, Columbus
Riverside Methodist Hospital, Columbus
Southwest Cardiology, Kettering
University Hospitals of Cleveland Case Medical Center, Cleveland
University of Cincinnati Medical Center, Cincinnati
University of Toledo, Toledo
VA Medical Center, Cleveland

Mental Illness—Leading Institutions Conducting Clinical Trials

Akron Children's Hospital, Akron
Charak Clinical Research Center, Beachwood, Garfield Heights
The Christ Hospital, Cincinnati
Cincinnati Addiction Research Center, Cincinnati
Cincinnati Children's Hospital Medical Center, Cincinnati
Cincinnati VA Medical Center, Cincinnati
Cleveland Clinic Sleep Disorders Center, Cleveland
Community Research, Cincinnati
Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati, Cincinnati
Lindner Center of HOPE at the University of Cincinnati, Cincinnati, Mason
Maryhaven, Columbus
Midwest Clinical Research Center, Dayton
Neuro-Behavioral Clinical Research, Canton
Neurology and Neuroscience Center of Ohio, Toledo
North Star Research, Middleburg Heights
NorthCoast Clinical Trials, Beachwood
Ohio Sleep Medicine Institute, Dublin
The Ohio State University Nisonger Center, Columbus
Patient Priority Clinical Sites, Cincinnati
Quest Therapeutics, Avon Lake
Radiant Research, Columbus
University Hospitals Case Medical Center, Cleveland
University Hospitals of Cleveland Medical Center, Cleveland
University of Cincinnati, Cincinnati
VA Medical Center, Cleveland

Stroke—Leading Institutions Conducting Clinical Trials

Case Western Reserve University, Cleveland
Cleveland Clinic Foundation, Cleveland
Lindner Clinic Trial Center, Cincinnati
Metrohealth Medical Center, Cleveland
The Ohio State University, Columbus
Riverside Methodist Hospital, Columbus
University of Cincinnati, Cincinnati
University of Toledo, Toledo

Appendix

The clinical trials listed here involve tests that have not yet started recruiting patients or are just now seeking volunteers to participate. This information is potentially valuable to patients still seeking effective treatments for their chronic diseases. It provides a new therapeutic option to discuss with physicians.

Those interested in obtaining more information about certain trials can use the URL code listed for each test to log onto *www.clinicaltrials.gov,* the clinical tests database of the National Institutes of Health.

Asthma

(20 clinical trials recruiting)

Study 1:

A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids

http://ClinicalTrials.gov/show/NCT01479621

Study 2:

A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications

http://ClinicalTrials.gov/show/NCT01576718

Study 3:

Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma

http://ClinicalTrials.gov/show/NCT00941798

Study 4:

A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations and Change in Lung Function in Patients (12-75 Years of Age) With Eosinophilic Asthma

http://ClinicalTrials.gov/show/NCT01287039

Study 5:

A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma

http://ClinicalTrials.gov/show/NCT00809757

Study 6:

A 6-week Study in Asthmatic Children Aged 6 to <12 Yrs Comparing Budesonide pMDI 160ug Twice Daily With Placebo

http://ClinicalTrials.gov/show/NCT01136382

Study 7:

A Study of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and A Second Controller Medication (VERSE)

http://ClinicalTrials.gov/show/NCT01545453

Study 8:

A Study of MEMP1972A in Patients With Allergic Asthma Inadequately Controlled on Inhaled Steroids And A Second Controller (COSTA)

http://ClinicalTrials.gov/show/NCT01582503

Study 9:

Safety Study in Adolescent and Adult Patients With Asthma

http://ClinicalTrials.gov/show/NCT01476904

Study 10:

Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent Asthma

http://ClinicalTrials.gov/show/NCT01257230

Study 11:

Efficacy, Safety, and Tolerability of SAR231893(REGN668) in Patients With Persistent Moderate to Severe Eosinophilic Asthma

http://ClinicalTrials.gov/show/NCT01312961

Study 12:

Evaluation of Tiotropium 2.5 and 5 Mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 Mcg Twice Daily) in Patient With Moderate Persistent Asthma II

http://ClinicalTrials.gov/show/NCT01172821

Study 13:

A Study of Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P04223 AM2)

http://ClinicalTrials.gov/show/NCT01502371

Study 14:

Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate and Fluticasone Propionate in People With Asthma

http://ClinicalTrials.gov/show/NCT01436110

Study 15:

A Study of Lebrikizumab in Patients Whose Asthma is Uncontrolled With Inhaled Corticosteroids and A Second Controller Medication (LUTE)

http://ClinicalTrials.gov/show/NCT01545440

Study 16:

A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12–75 Years of Age) With Eosinophilic Asthma

http://ClinicalTrials.gov/show/NCT01270464

Study 17:

A Study of ARRY-502 in Patients With Persistent Asthma

http://ClinicalTrials.gov/show/NCT01561690

Study 18:

New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day

http://ClinicalTrials.gov/show/NCT01360021

Study 19:

Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis

http://ClinicalTrials.gov/show/NCT01008410

Study 20:

Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis

http://ClinicalTrials.gov/show/NCT01008423

Cancer

(262 clinical trials recruiting)

Study 1:

Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer

http://ClinicalTrials.gov/show/NCT01284348

Study 2:

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

http://ClinicalTrials.gov/show/NCT00858364

Study 3:

A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer

http://ClinicalTrials.gov/show/NCT01111604

Study 4:

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

http://ClinicalTrials.gov/show/NCT00911170

Study 5:

Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer

http://ClinicalTrials.gov/show/NCT01217697

Study 6:

E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer

http://ClinicalTrials.gov/show/NCT01355302

Study 7:

Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)

http://ClinicalTrials.gov/show/NCT01082549

Study 8:

Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)

http://ClinicalTrials.gov/show/NCT01077154

Study 9:

ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer

http://ClinicalTrials.gov/show/NCT01244191

Study 10:

A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)

http://ClinicalTrials.gov/show/NCT01456325

Study 11:

A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer

http://ClinicalTrials.gov/show/NCT01246960

Study 12:

Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine

http://ClinicalTrials.gov/show/NCT01020006

Study 13:

Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer

http://ClinicalTrials.gov/show/NCT00045968

Study 14:

Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer

http://ClinicalTrials.gov/show/NCT01200992

Study 15:

A Study of MDV3100 Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer

http://ClinicalTrials.gov/show/NCT01288911

Study 16:

GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases

http://ClinicalTrials.gov/show/NCT01480583

Study 17:

Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)

http://ClinicalTrials.gov/show/NCT01355484

Study 18:

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

http://ClinicalTrials.gov/show/NCT01358877

Study 19:

Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum

http://ClinicalTrials.gov/show/NCT01355497

Study 20:

Efficacy and Safety of Zoledronic Acid (Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

http://ClinicalTrials.gov/show/NCT00320710

Study 21:

A Phase 3 Efficacy Study of a Recombinant Vaccinia Virus Vaccine to Treat Metastatic Prostate Cancer

http://ClinicalTrials.gov/show/NCT01322490

Study 22:

Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer

http://ClinicalTrials.gov/show/NCT01309126

Study 23:

Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic

http://ClinicalTrials.gov/show/NCT00696072

Study 24:

Immunotherapy Study for Surgically Resected Pancreatic Cancer

http://ClinicalTrials.gov/show/NCT01072981

Study 25:

Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer

http://ClinicalTrials.gov/show/NCT00878709

Study 26:

Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)

http://ClinicalTrials.gov/show/NCT01170650

Study 27:

Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer

http://ClinicalTrials.gov/show/NCT01348126

Study 28:

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

http://ClinicalTrials.gov/show/NCT01314118

Study 29:

A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer

http://ClinicalTrials.gov/show/NCT01268059

Study 30:

A Multicenter Clinical Study of the Sonablate®500 for the Treatment of Locally Recurrent Prostate Cancer With HIFU

http://ClinicalTrials.gov/show/NCT00772317

Study 31:

A Study of Paclitaxel/Carboplatin With or Without IMC-3G3 in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

http://ClinicalTrials.gov/show/NCT00918203

Study 32:

Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer

http://ClinicalTrials.gov/show/NCT00965731

Study 33:

Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients

http://ClinicalTrials.gov/show/NCT01234402

Study 34:

Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer

http://ClinicalTrials.gov/show/NCT01446159

Study 35:

A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy

http://ClinicalTrials.gov/show/NCT01381874

Study 36:

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

http://ClinicalTrials.gov/show/NCT01374425

Study 37:

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

http://ClinicalTrials.gov/show/NCT01308567

Study 38:

A Study of Avastin (Bevacizumab) in Combination With Standard of Care Treatment in Patients With Lung Cancer

http://ClinicalTrials.gov/show/NCT01351415

Study 39:

Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)

http://ClinicalTrials.gov/show/NCT01387282

Study 40:

Study Evaluating the Safety and Efficacy Of Carboplatin/Paclitaxel And Carboplatin/Paclitaxel/ Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced Or Recurrent Non-small Cell Lung Cancer

http://ClinicalTrials.gov/show/NCT01493843

Study 41:

A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer

http://ClinicalTrials.gov/show/NCT01519804

Study 42:

Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer

http://ClinicalTrials.gov/show/NCT01471197

Study 43:

A Phase 2b Study of Modified Vaccinia Virus to Treat Advanced Liver Cancer

http://ClinicalTrials.gov/show/NCT01387555

Study 44:

A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer

http://ClinicalTrials.gov/show/NCT00770536

Study 45:

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

http://ClinicalTrials.gov/show/NCT00807859

Study 46:

A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers

http://ClinicalTrials.gov/show/NCT01447706

Study 47:

Study of Patients With Advanced Non-Small Cell Lung Cancer

http://ClinicalTrials.gov/show/NCT00948675

Study 48:

Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy

http://ClinicalTrials.gov/show/NCT00676507

Study 49:

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

http://ClinicalTrials.gov/show/NCT01522443

Study 50:

A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck

http://ClinicalTrials.gov/show/NCT01059643

Study 51:

Comparison of Docetaxel/Prednisone to Docetaxel/ Prednisone in Combination With OGX-011 in Men With Prostate Cancer

http://ClinicalTrials.gov/show/NCT01188187

Study 52:

Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer

http://ClinicalTrials.gov/show/NCT01410565

Study 53:

A Study of ARRY-438162 (MEK162) in Patients With Advanced Cancer

http://ClinicalTrials.gov/show/NCT00959127

Study 54:

A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine for 3rd Line Treatment of Patients With Metastatic Pancreatic Cancer

http://ClinicalTrials.gov/show/NCT01510561

Study 55:

A Study of Chemotherapy and Ramucirumab vs. Chemotherapy Alone in Second Line Non-small Cell Lung Cancer Patients Who Received Prior First Line Platinum Based Chemotherapy

http://ClinicalTrials.gov/show/NCT01168973

Study 56:

Efficacy & Safety Study of MORAb-004 to Treat Metastatic Colorectal Cancer

http://ClinicalTrials.gov/show/NCT01507545

Study 57:

Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Cancer

http://ClinicalTrials.gov/show/NCT01013324

Study 58:

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

http://ClinicalTrials.gov/show/NCT00925600

Study 59:

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

http://ClinicalTrials.gov/show/NCT01478594

Study 60:

The BEACON Study (Breast Cancer Outcomes With NKTR-102)

http://ClinicalTrials.gov/show/NCT01492101

Study 61:

Combination With Gemcitabine in Advanced Pancreatic Cancer

http://ClinicalTrials.gov/show/NCT01251640

Study 62:

A Phase 1b Study of MDX-1106 in Subjects With Advanced or Recurrent Malignancies

http://ClinicalTrials.gov/show/NCT00730639

Study 63:

A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer

http://ClinicalTrials.gov/show/NCT01496742

Study 64:

EMD525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer

http://ClinicalTrials.gov/show/NCT01360840

Study 65:

Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy

http://ClinicalTrials.gov/show/NCT00891137

Study 66:

Study of MM-398 Versus 5-Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer

http://ClinicalTrials.gov/show/NCT01494506

Study 67:

TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)

http://ClinicalTrials.gov/show/NCT01194960

Study 68:

Safety and Efficacy of Cryoablation for Abdominal Pain Associated With Pancreatic Cancer

http://ClinicalTrials.gov/show/NCT01335945

Study 69:

A Study in Second Line Metastatic Colorectal Cancer

http://ClinicalTrials.gov/show/NCT01183780

Study 70:

Study of REOLYSIN® in Combination With FOLFIRI in Patients With Oxaliplatin Refractory/Intolerant KRAS Mutant Colorectal Cancer

http://ClinicalTrials.gov/show/NCT01274624

Study 71:

A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer

http://ClinicalTrials.gov/show/NCT01181245

Study 72:

Efficacy & Safety of ODSH (2-0, 3-0 Desulfated Heparin) in Patients With Metastatic Pancreatic Cancer Treated With Gemcitabine & Abraxane

http://ClinicalTrials.gov/show/NCT01461915

Study 73:

A Study of LY2523355 in Patients With Breast Cancer

http://ClinicalTrials.gov/show/NCT01416389

Study 74:

A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer

http://ClinicalTrials.gov/show/NCT01362400

Study 75:

Long Term Safety of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain

http://ClinicalTrials.gov/show/NCT01337089

Study 76:

A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer

http://ClinicalTrials.gov/show/NCT01427933

Study 77:

Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)

http://ClinicalTrials.gov/show/NCT01234025

Study 78:

Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel

http://ClinicalTrials.gov/show/NCT01234038

Study 79:

Efficacy and Safety of a Sunscreen Against Porfimer Sodium-induced Phototoxicity to Visible Light

http://ClinicalTrials.gov/show/NCT01256203

Study 80:

A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer

http://ClinicalTrials.gov/show/NCT01234311

Study 81:

A Trial of E7080 (Lenvatinib) in 131I-Refractory Differentiated Thyroid Cancer

http://ClinicalTrials.gov/show/NCT01321554

Study 82:

Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer

http://ClinicalTrials.gov/show/NCT01193257

Study 83:

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

http://ClinicalTrials.gov/show/NCT01308580

Study 84:

Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer

http://ClinicalTrials.gov/show/NCT01297491

Study 85:

Chemotherapy and Radiation in Treating Patients With Stage 3 Non-Small Cell Lung Cancer

http://ClinicalTrials.gov/show/NCT00686959

Study 86:

Efficacy/Safety of Imprime PGG® Injection With Bevacizumab and Paclitaxel/Carboplatin in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)

http://ClinicalTrials.gov/show/NCT00874107

Study 87:

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer

http://ClinicalTrials.gov/show/NCT01565083

Study 88:

A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Patients With HER2-Positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-Directed Therapy (TH3RESA)

http://ClinicalTrials.gov/show/NCT01419197

Study 89:

Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin

http://ClinicalTrials.gov/show/NCT01285609

Study 90:

Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients

http://ClinicalTrials.gov/show/NCT01169584

Study 91:

A Phase I Study to Assess the Safety and Distribution of VB-111 in Patients With Advanced Metastatic Cancer

http://ClinicalTrials.gov/show/NCT00559117

Study 92:

Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

http://ClinicalTrials.gov/show/NCT01221077

Study 93:

A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011 AM1)

http://ClinicalTrials.gov/show/NCT01254630

Study 94:

Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function

http://ClinicalTrials.gov/show/NCT00652626

Study 95:

NP2 Enkephalin For Treatment of Intractable Cancer Pain

http://ClinicalTrials.gov/show/NCT01291901

Study 96:

Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation

http://ClinicalTrials.gov/show/NCT00861627

Study 97:

A Study in Head and Neck Cancer

http://ClinicalTrials.gov/show/NCT01081041

Study 98:

A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer

http://ClinicalTrials.gov/show/NCT00994123

Study 99:

A Study of IMC-CS4 in Subjects With Advanced Solid Tumors

http://ClinicalTrials.gov/show/NCT01346358

Study 100:

Efficacy and Safety of Masitinib (AB1010) in Comparison to Imatinib in Patients With Gastro-intestinal Stromal Tumour

http://ClinicalTrials.gov/show/NCT00812240

Study 101:

Phase 2 Study of Thermodox as Adjuvant Therapy With Radiofrequency Ablation (RFA) in Treatment of Colorectal Liver Metastases (CRLM)

http://ClinicalTrials.gov/show/NCT01464593

Study 102:

LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment

http://ClinicalTrials.gov/show/NCT01125566

Study 103:

Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE)

http://ClinicalTrials.gov/show/NCT01366131

Study 104:

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

http://ClinicalTrials.gov/show/NCT01461538

Study 105:

Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6)

http://ClinicalTrials.gov/show/NCT00871663

Study 106:

A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors

http://ClinicalTrials.gov/show/NCT01231594

Study 107:

Dose Escalation Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies

http://ClinicalTrials.gov/show/NCT01084252

Study 108:

A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3

http://ClinicalTrials.gov/show/NCT01304524

Study 109:

A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer

http://ClinicalTrials.gov/show/NCT01087970

Study 110:

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

http://ClinicalTrials.gov/show/NCT01479465

Study 111:

An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

http://ClinicalTrials.gov/show/NCT00932451

Study 112:

Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients

http://ClinicalTrials.gov/show/NCT00428922

Study 113:

A Phase 1 Dose Escalation Study of AMG 780 in Adult Subjects With Advanced Solid Tumor

http://ClinicalTrials.gov/show/NCT01137552

Study 114:

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

http://ClinicalTrials.gov/show/NCT01360853

Study 115:

Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors

http://ClinicalTrials.gov/show/NCT01447225

Study 116:

Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects

http://ClinicalTrials.gov/show/NCT01403064

Study 117:

A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors

http://ClinicalTrials.gov/show/NCT01340846

Study 118:

Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer

http://ClinicalTrials.gov/show/NCT00825734

Study 119:

A Study to Evaluate the Effects of Combining Cabazitaxel With Cisplatin Given Every 3 Weeks in Patients With Advanced Solid Cancer

http://ClinicalTrials.gov/show/NCT00925743

Study 120:

Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together With Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Smal Cell Lung Cancer)

http://ClinicalTrials.gov/show/NCT01573338

Study 121:

Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer

http://ClinicalTrials.gov/show/NCT00924352

Study 122:

Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer

http://ClinicalTrials.gov/show/NCT01033032

Study 123:

Study of Pazopanib and Doxil in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma

http://ClinicalTrials.gov/show/NCT01035658

Study 124:

Trial of Poor Performance Status Patients (ToPPS)

http://ClinicalTrials.gov/show/NCT00892710

Study 125:

Study of Ruxolitinib in Pancreatic Cancer Patients

http://ClinicalTrials.gov/show/NCT01423604

Study 126:

Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer

http://ClinicalTrials.gov/show/NCT00894504

Study 127:

Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone

http://ClinicalTrials.gov/show/NCT01450761

Study 128:

A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)

http://ClinicalTrials.gov/show/NCT01235962

Study 129:

A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver

http://ClinicalTrials.gov/show/NCT00803647

Study 130:

FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

http://ClinicalTrials.gov/show/NCT01226719

Study 131:

Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer

http://ClinicalTrials.gov/show/NCT00754923

Study 132:

Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer

http://ClinicalTrials.gov/show/NCT00824733

Study 133:

Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies

http://ClinicalTrials.gov/show/NCT01188252

Study 134:

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

http://ClinicalTrials.gov/show/NCT01074970

Study 135:

First in Man Study of SAR566658 Administered Every 3 Weeks in Patients With DS6-positive and Refractory Solid Tumors

http://ClinicalTrials.gov/show/NCT01156870

Study 136:

Dose Escalation Study of ARQ 736 in Adult Subjects With Advanced Solid Tumors Harboring BRAF and/or NRAS Mutations

http://ClinicalTrials.gov/show/NCT01225536

Study 137:

Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer

http://ClinicalTrials.gov/show/NCT00906282

Study 138:

Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment

http://ClinicalTrials.gov/show/NCT01140607

Study 139:

Study of Breast Cancer Prevention by Letrozole in High Risk Women

http://ClinicalTrials.gov/show/NCT00579826

Study 140:

Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)

http://ClinicalTrials.gov/show/NCT01379209

Study 141:

Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLC

http://ClinicalTrials.gov/show/NCT01042288

Study 142:

A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function

http://ClinicalTrials.gov/show/NCT01331941

Study 143:

Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors

http://ClinicalTrials.gov/show/NCT01508104

Study 144:

Multiple Ascending Dose (MDX1105-01)

http://ClinicalTrials.gov/show/NCT00729664

Study 145:

A Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies

http://ClinicalTrials.gov/show/NCT01204164

Study 146:

Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR

http://ClinicalTrials.gov/show/NCT00567359

Study 147:

Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

http://ClinicalTrials.gov/show/NCT00515411

Study 148:

Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis

http://ClinicalTrials.gov/show/NCT01437787

Study 149:

A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in NNSCC

http://ClinicalTrials.gov/show/NCT00882583

Study 150:

Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse

http://ClinicalTrials.gov/show/NCT01217203

Study 151:

Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme

http://ClinicalTrials.gov/show/NCT00895180

Study 152:

Single Treatment With FT1050 of an Ex-vivo Modultated Umbilical Cord Blood Unit

http://ClinicalTrials.gov/show/NCT01527838

Study 153:

A Study of Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer

http://ClinicalTrials.gov/show/NCT01262651

Study 154:

A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts

http://ClinicalTrials.gov/show/NCT01007552

Study 155:

A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain

http://ClinicalTrials.gov/show/NCT00929188

Study 156:

Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers

http://ClinicalTrials.gov/show/NCT01166542

Study 157:

Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)

http://ClinicalTrials.gov/show/NCT01212380

Study 158:

Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

http://ClinicalTrials.gov/show/NCT00729118

Study 159:

A Study Of Panobinostat In Children With Refractory Hematologic Malignancies

http://ClinicalTrials.gov/show/NCT01321346

Study 160:

Study of a Retroviral Replicating Vector to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor

http://ClinicalTrials.gov/show/NCT01470794

Study 161:

A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer

http://ClinicalTrials.gov/show/NCT01304784

Study 162:

An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study

http://ClinicalTrials.gov/show/NCT01090414

Study 163:

A Study of LY2510924 in Patients With Extensive-Stage Small Cell Lung Carcinoma

http://ClinicalTrials.gov/show/NCT01439568

Study 164:

IMA901 in Patients Receiving Sunitinib for Advanced/ Metastatic Renal Cell Carcinoma

http://ClinicalTrials.gov/show/NCT01265901

Study 165:

Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma

http://ClinicalTrials.gov/show/NCT01428492

Study 166:

A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung

http://ClinicalTrials.gov/show/NCT00998192

Study 167:

Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma

http://ClinicalTrials.gov/show/NCT00911326

Study 168:

Study of Oral MLN9708 in Combination With Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

http://ClinicalTrials.gov/show/NCT01383928

Study 169:

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

http://ClinicalTrials.gov/show/NCT01335399

Study 170:

A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

http://ClinicalTrials.gov/show/NCT01484275

Study 171:

A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma

http://ClinicalTrials.gov/show/NCT01391130

Study 172:

An SGN-35 Trial for Patients Who Have Previously Participated in an SGN-35 Study

http://ClinicalTrials.gov/show/NCT00947856

Study 173:

E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma

http://ClinicalTrials.gov/show/NCT01271504

Study 174:

Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)

http://ClinicalTrials.gov/show/NCT00916409

Study 175:

A Study of a Retroviral Replicating Vector Administered to Subjects With Recurrent Malignant Glioma

http://ClinicalTrials.gov/show/NCT01156584

Study 176:

Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma

http://ClinicalTrials.gov/show/NCT01199718

Study 177:

Phase I Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

http://ClinicalTrials.gov/show/NCT00461045

Study 178:

Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

http://ClinicalTrials.gov/show/NCT01497093

Study 179:

Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma

http://ClinicalTrials.gov/show/NCT01480479

Study 180:

A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma

http://ClinicalTrials.gov/show/NCT01498328

Study 181:

Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma

http://ClinicalTrials.gov/show/NCT01108445

Study 182:

Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (AML)

http://ClinicalTrials.gov/show/NCT01191801

Study 183:

Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

http://ClinicalTrials.gov/show/NCT01471782

Study 184:

Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma

http://ClinicalTrials.gov/show/NCT01177683

Study 185:

Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia

http://ClinicalTrials.gov/show/NCT01158885

Study 186:

Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia

http://ClinicalTrials.gov/show/NCT01351935

Study 187:

Neoadjuvant Pazopanib in Renal Cell Carcinoma

http://ClinicalTrials.gov/show/NCT01361113

Study 188:

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

http://ClinicalTrials.gov/show/NCT01369329

Study 189:

Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients

http://ClinicalTrials.gov/show/NCT01508117

Study 190:

A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

http://ClinicalTrials.gov/show/NCT01466153

Study 191:

A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

http://ClinicalTrials.gov/show/NCT01453205

Study 192:

Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)

http://ClinicalTrials.gov/show/NCT00585312

Study 193:

A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)

http://ClinicalTrials.gov/show/NCT01280552

Study 194:

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

http://ClinicalTrials.gov/show/NCT01136967

Study 195:

Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma

http://ClinicalTrials.gov/show/NCT01210495

Study 196:

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

http://ClinicalTrials.gov/show/NCT01028222

Study 197:

A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma

http://ClinicalTrials.gov/show/NCT01343277

Study 198:

An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting

http://ClinicalTrials.gov/show/NCT01339260

Study 199:

Safety and Efficacy Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids

http://ClinicalTrials.gov/show/NCT01441635

Study 200:

A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma

http://ClinicalTrials.gov/show/NCT01297244

Study 201:

BMS-936558 (MDX-1106) In Combination With Sunitinib or Pazopanib in Subjects With Metastatic Renal Cell Carcinoma (RCC)

http://ClinicalTrials.gov/show/NCT01472081

Study 202:

Evaluation of TRC105 In The Treatment Of Recurrent Glioblastoma After Prior Antiangiogenic Therapy (Including Anti-VEGF Therapy)

http://ClinicalTrials.gov/show/NCT01564914

Study 203:

Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma

http://ClinicalTrials.gov/show/NCT01124539

Study 204:

A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Patients With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib

http://ClinicalTrials.gov/show/NCT01140347

Study 205:

Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma

http://ClinicalTrials.gov/show/NCT01168791

Study 206:

An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting

http://ClinicalTrials.gov/show/NCT01363479

Study 207:

Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL

http://ClinicalTrials.gov/show/NCT00546793

Study 208:

A Study of IMC-3G3 in Soft Tissue Sarcoma

http://ClinicalTrials.gov/show/NCT01185964

Study 209:

Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma

http://ClinicalTrials.gov/show/NCT01327885

Study 210:

Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free

http://ClinicalTrials.gov/show/NCT01141491

Study 211:

Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Post-remission Chemotherapy for Leukemia

http://ClinicalTrials.gov/show/NCT01297543

Study 212:

Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia

http://ClinicalTrials.gov/show/NCT01188681

Study 213:

A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy

http://ClinicalTrials.gov/show/NCT01232556

Study 214:

A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)

http://ClinicalTrials.gov/show/NCT01100502

Study 215:

A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma

http://ClinicalTrials.gov/show/NCT01059630

Study 216:

A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung

http://ClinicalTrials.gov/show/NCT00752206

Study 217:

Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant

http://ClinicalTrials.gov/show/NCT01321541

Study 218:

A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell CLL Following Second Line Therapy (THE CONTINUUM TRIAL)

http://ClinicalTrials.gov/show/NCT00774345

Study 219:

Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia

http://ClinicalTrials.gov/show/NCT01460160

Study 220:

Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy

http://ClinicalTrials.gov/show/NCT00790036

Study 221:

Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

http://ClinicalTrials.gov/show/NCT00963105

Study 222:

Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine

http://ClinicalTrials.gov/show/NCT01519011

Study 223:

Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients

http://ClinicalTrials.gov/show/NCT00931918

Study 224:

A Study of RO5072759 (GA101) in Combination With CHOP Chemotherapy Versus MabThera/Rituxan (Rituximab) With CHOP in Patients With CD20-Positive Diffuse Large B-Cell Lymphoma

http://ClinicalTrials.gov/show/NCT01287741

Study 225:

Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma

http://ClinicalTrials.gov/show/NCT01482962

Study 226:

Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma

http://ClinicalTrials.gov/show/NCT01506596

Study 227:

Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)

http://ClinicalTrials.gov/show/NCT01242774

Study 228:

Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)

http://ClinicalTrials.gov/show/NCT01433731

Study 229:

A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)

http://ClinicalTrials.gov/show/NCT01087151

Study 230:

Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia

http://ClinicalTrials.gov/show/NCT01363297

Study 231:

Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts

http://ClinicalTrials.gov/show/NCT01241500

Study 232:

Safety and Efficacy Study of Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma

http://ClinicalTrials.gov/show/NCT01325701

Study 233:

A Study Comparing RO5072759 (GA101) 1000 mg Versus 2000 mg in Patients With Previously Untreated Chronic Lymphocytic Leukemia

http://ClinicalTrials.gov/show/NCT01414205

Study 234:

Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)

http://ClinicalTrials.gov/show/NCT00910910

Study 235:

Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia

http://ClinicalTrials.gov/show/NCT01161511

Study 236:

A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia

http://ClinicalTrials.gov/show/NCT01403636

Study 237:

Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects

http://ClinicalTrials.gov/show/NCT01177540

Study 238:

Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma

http://ClinicalTrials.gov/show/NCT01402440

Study 239:

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

http://ClinicalTrials.gov/show/NCT01077544

Study 240:

Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia

http://ClinicalTrials.gov/show/NCT00990054

Study 241:

Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)

http://ClinicalTrials.gov/show/NCT01357655

Study 242:

A Study of Brentuximab Vedotin in Patients With CD30-positive Non-Hodgkin Lymphoma

http://ClinicalTrials.gov/show/NCT01421667

Study 243:

Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)

http://ClinicalTrials.gov/show/NCT01294579

Study 244:

Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy

http://ClinicalTrials.gov/show/NCT01200589

Study 245:

A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment

http://ClinicalTrials.gov/show/NCT01007292

Study 246:

Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma

http://ClinicalTrials.gov/show/NCT01479842

Study 247:

Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL

http://ClinicalTrials.gov/show/NCT00981799

Study 248:

Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma

http://ClinicalTrials.gov/show/NCT01186458

Study 249:

Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma

http://ClinicalTrials.gov/show/NCT01029730

Study 250:

A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma

http://ClinicalTrials.gov/show/NCT01460940

Study 251:

Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma

http://ClinicalTrials.gov/show/NCT01129180

Study 252:

Bortezomib and Midostaurin With or Without Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

http://ClinicalTrials.gov/show/NCT01174888

Study 253:

Phase II R-ABVD Versus ABVD for Advanced Stage Classical Hodgkin Lymphoma

http://ClinicalTrials.gov/show/NCT00654732

Study 254:

Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)

http://ClinicalTrials.gov/show/NCT00628238

Study 255:

A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

http://ClinicalTrials.gov/show/NCT01411267

Study 256:

Multi-center Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

http://ClinicalTrials.gov/show/NCT01199575

Study 257:

Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL

http://ClinicalTrials.gov/show/NCT01523977

Study 258:

A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome

http://ClinicalTrials.gov/show/NCT01513317

Study 259:

Short-incubation Levulan Photodynamic Therapy Versus Vehicle for Face/Scalp Actinic Keratosis (AK)

http://ClinicalTrials.gov/show/NCT01475955

Study 260:

A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes

http://ClinicalTrials.gov/show/NCT01496495

Study 261:

Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC)

http://ClinicalTrials.gov/show/NCT01289912

Study 262:

Electrical Stimulation of the Sphenopalatine Ganglion for the Treatment of Migraine Headaches

http://ClinicalTrials.gov/show/NCT01294046

Diabetes

(53 clinical trials recruiting)

Study 1:

A Study in Patients With Type 2 Diabetes Mellitus

http://ClinicalTrials.gov/show/NCT01435616

Study 2:

A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus

http://ClinicalTrials.gov/show/NCT01513473

Study 3:

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes

http://ClinicalTrials.gov/show/NCT01204775

Study 4:

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

http://ClinicalTrials.gov/show/NCT01394952

Study 5:

CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes

http://ClinicalTrials.gov/show/NCT01243424

Study 6:

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

http://ClinicalTrials.gov/show/NCT01195662

Study 7:

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

http://ClinicalTrials.gov/show/NCT01137474

Study 8:

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients

http://ClinicalTrials.gov/show/NCT01131676

Study 9:

A Study in Participants With Type 2 Diabetes Mellitus

http://ClinicalTrials.gov/show/NCT01468987

Study 10:

Safety and Efficacy of BI 10773 and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes

http://ClinicalTrials.gov/show/NCT01289990

Study 11:

Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients

http://ClinicalTrials.gov/show/NCT01422876

Study 12:

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

http://ClinicalTrials.gov/show/NCT01434186

Study 13:

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

http://ClinicalTrials.gov/show/NCT01144338

Study 14:

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

http://ClinicalTrials.gov/show/NCT00968708

Study 15:

Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes

http://ClinicalTrials.gov/show/NCT01351675

Study 16:

Efficacy and Safety of Azilsartan Medoxomil Used in Combination With Metformin in Participants With Hypertension and Diabetes

http://ClinicalTrials.gov/show/NCT01496430

Study 17:

Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults

http://ClinicalTrials.gov/show/NCT01103284

Study 18:

A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

http://ClinicalTrials.gov/show/NCT01042769

Study 19:

Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes Mellitus

http://ClinicalTrials.gov/show/NCT01414920

Study 20:

Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus

http://ClinicalTrials.gov/show/NCT00789750

Study 21:

Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin

http://ClinicalTrials.gov/show/NCT01517373

Study 22:

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin

http://ClinicalTrials.gov/show/NCT01499082

Study 23:

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy

http://ClinicalTrials.gov/show/NCT01499095

Study 24:

Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes

http://ClinicalTrials.gov/show/NCT00658021

Study 25:

Study to Assess Safety & Efficacy of Sitagliptin as Initial Monotherapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants (MK-0431-083)

http://ClinicalTrials.gov/show/NCT01485614

Study 26:

AMG 151 Amgen Protocol Number 20100761

http://ClinicalTrials.gov/show/NCT01464437

Study 27:

Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes

http://ClinicalTrials.gov/show/NCT01576328

Study 28:

Finding a Safe and Effective Dose of Linagliptin in Peadiatric Patients With Type 2 Diabetes

http://ClinicalTrials.gov/show/NCT01342484

Study 29:

A Study in Patients With Type I Diabetes Mellitus

http://ClinicalTrials.gov/show/NCT01454284

Study 30:

Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug—PF04937319 In Patients With Type 2 Diabetes

http://ClinicalTrials.gov/show/NCT01475461

Study 31:

Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

http://ClinicalTrials.gov/show/NCT01472185

Study 32:

A Phase III Study to Evaluate Safety, Tolerability and Efficacy of CureXcell™ in Treating Lower Extremity Chronic Ulcers in Adults With Diabetes Mellitus

http://ClinicalTrials.gov/show/NCT01421966

Study 33:

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

http://ClinicalTrials.gov/show/NCT01494987

Study 34:

Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes

http://ClinicalTrials.gov/show/NCT01456195

Study 35:

Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

http://ClinicalTrials.gov/show/NCT01481116

Study 36:

Comparison of Technosphere Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus

http://ClinicalTrials.gov/show/NCT01451398

Study 37:

Pharmacokinetics/Pharmacodynamics of Albiglutide

http://ClinicalTrials.gov/show/NCT01357889

Study 38:

30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes

http://ClinicalTrials.gov/show/NCT01183013

Study 39:

A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients

http://ClinicalTrials.gov/show/NCT01487109

Study 40:

Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients

http://ClinicalTrials.gov/show/NCT01515657

Study 41:

Sitagliptin Cardiovascular Outcome Study (0431-082 AM1)

http://ClinicalTrials.gov/show/NCT00790205

Study 42:

Outpatient Study to Evaluate Safety and Effectiveness of the Low Glucose Suspend Feature

http://ClinicalTrials.gov/show/NCT01497938

Study 43:

Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients

http://ClinicalTrials.gov/show/NCT00995930

Study 44:

Insulin Resistance Intervention After Stroke Trial

http://ClinicalTrials.gov/show/NCT00091949

Study 45:

A Study in Patients With Diabetic Kidney Disease

http://ClinicalTrials.gov/show/NCT01113801

Study 46:

Prevention of Cystic Fibrosis Diabetes

http://ClinicalTrials.gov/show/NCT00967798

Study 47:

Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

http://ClinicalTrials.gov/show/NCT01496365

Study 48:

Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)

http://ClinicalTrials.gov/show/NCT01147250

Study 49:

Transdermal Continuous Oxygen Therapy for Diabetic Foot Ulcers

http://ClinicalTrials.gov/show/NCT01291160

Study 50:

Effect Of Pregabalin Treatment In Patients With Diabetic Nerve Pain Who Currently Use A Non-Steroid Anti-Inflammatory Drug (NSAID) For Another Pain

http://ClinicalTrials.gov/show/NCT01455415

Study 51:

Efficacy and Safety Study of Pregabalin in the Treatment of Pain on Walking in Patients With Diabetic Peripheral Neuropathy (DPN)

http://ClinicalTrials.gov/show/NCT01474772

Study 52:

A Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy

http://ClinicalTrials.gov/show/NCT01399580

Study 53:

Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy

http://ClinicalTrials.gov/show/NCT01489189

Heart Disease

(44 clinical trials recruiting)

Study 1:

A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease

http://ClinicalTrials.gov/show/NCT01516541

Study 2:

Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina

http://ClinicalTrials.gov/show/NCT01508910

Study 3:

Use of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risks

http://ClinicalTrials.gov/show/NCT01218802

Study 4:

Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/ Emergency Department Visits or Cardiovascular Death in Patients With Implantable Cardioverter Defibrillators (ICDs)

http://ClinicalTrials.gov/show/NCT01464476

Study 5:

A Study of RO4905417 in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery

http://ClinicalTrials.gov/show/NCT01245634

Study 6:

A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

http://ClinicalTrials.gov/show/NCT01042769

Study 7:

Echocardiography Guided Cardiac Resynchronization Therapy (EchoCRT)

http://ClinicalTrials.gov/show/NCT00683696

Study 8:

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

http://ClinicalTrials.gov/show/NCT01225562

Study 9:

Safety and Efficacy Continued Access Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in Very High Risk Subjects Who Need Aortic Valve Replacement

http://ClinicalTrials.gov/show/NCT01531374

Study 10:

Clinical Evaluation of the Blazer® Open-Irrigated Catheter for Treatment of Type 1 Atrial Flutter

http://ClinicalTrials.gov/show/NCT01253200

Study 11:

The Evaluation of VAD InterVEntion Before Inotropic Therapy

http://ClinicalTrials.gov/show/NCT01369407

Study 12:

Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI

http://ClinicalTrials.gov/show/NCT00990327

Study 13:

RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial

http://ClinicalTrials.gov/show/NCT00358215

Study 14:

A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD

http://ClinicalTrials.gov/show/NCT01347710

Study 15:

Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)

http://ClinicalTrials.gov/show/NCT01442038

Study 16:

Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure

http://ClinicalTrials.gov/show/NCT01300013

Study 17:

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

http://ClinicalTrials.gov/show/NCT00968708

Study 18:

AngelMed for Early Recognition and Treatment of STEMI

http://ClinicalTrials.gov/show/NCT00781118

Study 19:

Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure

http://ClinicalTrials.gov/show/NCT00803634

Study 20:

Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy

http://ClinicalTrials.gov/show/NCT01121107

Study 21:

Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)

http://ClinicalTrials.gov/show/NCT01147250

Study 22:

Post-Myocardial Infarction Remodeling Prevention Therapy

http://ClinicalTrials.gov/show/NCT01213251

Study 23:

INcrease Of VAgal TonE in CHF

http://ClinicalTrials.gov/show/NCT01303718

Study 24:

A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction (Non-STEMI) Undergoing Percutaneous Coronary Intervention

http://ClinicalTrials.gov/show/NCT01327183

Study 25:

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

http://ClinicalTrials.gov/show/NCT01327846

Study 26:

AMR-001 Versus Placebo Post ST Segment Elevation Myocardial Infarction

http://ClinicalTrials.gov/show/NCT01495364

Study 27:

The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves

http://ClinicalTrials.gov/show/NCT01314313

Study 28:

Vest Prevention of Early Sudden Death Trial and VEST Registry

http://ClinicalTrials.gov/show/NCT01446965

Study 29:

Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy

http://ClinicalTrials.gov/show/NCT01182441

Study 30:

Clinical Evaluation of Therapy™ Cool Flex™ Irrigated Ablation System for the Treatment of Typical Atrial Flutter

http://ClinicalTrials.gov/show/NCT01408485

Study 31:

Evaluate the Safety and Efficacy of OAS in Treating Severely Calcified Coronary Lesions

http://ClinicalTrials.gov/show/NCT01092416

Study 32:

Intravenous L-Citrulline to Treat Children Undergoing Heart Bypass Surgery : Revised Protocol

http://ClinicalTrials.gov/show/NCT01120964

Study 33:

A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure

http://ClinicalTrials.gov/show/NCT01357850

Study 34:

Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy

http://ClinicalTrials.gov/show/NCT01076764

Study 35:

Cardiox Shunt Detection Technology Study

http://ClinicalTrials.gov/show/NCT01333761

Study 36:

ABLATE AF Registry Trial

http://ClinicalTrials.gov/show/NCT01174745

Study 37:

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

http://ClinicalTrials.gov/show/NCT01522651

Study 38:

Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management

http://ClinicalTrials.gov/show/NCT01584557

Study 39:

Insulin Resistance Intervention After Stroke Trial

http://ClinicalTrials.gov/show/NCT00091949

Study 40:

A Study on the Pharmacokinetics and Safety of Valcyte (Valganciclovir) in Pediatric Heart Transplant Recipients Less Than 4 Months of Age

http://ClinicalTrials.gov/show/NCT01165580

Study 41:

Safety & Efficacy of BCT197 in Patients Undergoing Cardiac Surgery

http://ClinicalTrials.gov/show/NCT01336959

Study 42:

Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced Thrombocytopenia

http://ClinicalTrials.gov/show/NCT00886743

Study 43:

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

http://ClinicalTrials.gov/show/NCT01101035

Study 44:

Aliskiren Effect on Plaque Progression In Established Atherosclerosis Using High Resolution 3D MRI (ALPINE)

http://ClinicalTrials.gov/show/NCT01417104

Mental Illness

(86 clinical trials recruiting)

Study 1:

Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)

http://ClinicalTrials.gov/show/NCT01360632

Study 2:

Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)

http://ClinicalTrials.gov/show/NCT01360866

Study 3:

Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)

http://ClinicalTrials.gov/show/NCT01360645

Study 4:

SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)

http://ClinicalTrials.gov/show/NCT01470469

Study 5:

Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism

http://ClinicalTrials.gov/show/NCT00872898

Study 6:

Study of Rufinamide in Pediatric Subjects 1 to Less Than 4 Years of Age With Lennox-Gastaut Syndrome Inadequately Controlled With Other Anti-epileptic Drugs

http://ClinicalTrials.gov/show/NCT01405053

Study 7:

A Study to Evaluate the Efficacy and Safety of Molindone Hydrochloride XR Tablets as Adjunctive Therapy in Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder (ADHD)

http://ClinicalTrials.gov/show/NCT01364662

Study 8:

Safety & Efficacy of TC-5619 in Adults With Inattentive-predominant Attention Deficit/ Hyperactivity Disorder (ADHD)

http://ClinicalTrials.gov/show/NCT01472991

Study 9:

Ecopipam Treatment of Tourette Syndrome

http://ClinicalTrials.gov/show/NCT01244633

Study 10:

Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders

http://ClinicalTrials.gov/show/NCT01288716

Study 11:

Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl

http://ClinicalTrials.gov/show/NCT01081132

Study 12:

Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)

http://ClinicalTrials.gov/show/NCT01081145

Study 13:

Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette's Syndrome

http://ClinicalTrials.gov/show/NCT01475383

Study 14:

A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis

http://ClinicalTrials.gov/show/NCT01174004

Study 15:

Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features.

http://ClinicalTrials.gov/show/NCT01122927

Study 16:

A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

http://ClinicalTrials.gov/show/NCT00550238

Study 17:

A Paroxetine- and Placebo-Controlled Study of 50 mg/ Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)

http://ClinicalTrials.gov/show/NCT01318434

Study 18:

Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder

http://ClinicalTrials.gov/show/NCT01428661

Study 19:

A Long-Term, Open-Label, Study on Schizophrenia

http://ClinicalTrials.gov/show/NCT01129674

Study 20:

Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression

http://ClinicalTrials.gov/show/NCT01396447

Study 21:

Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder

http://ClinicalTrials.gov/show/NCT01469377

Study 22:

Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM2)

http://ClinicalTrials.gov/show/NCT01349907

Study 23:

Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder {P06107 Has an Extension (P05898; NCT01349907}(P06107 AM2)

http://ClinicalTrials.gov/show/NCT01244815

Study 24:

Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

http://ClinicalTrials.gov/show/NCT01121536

Study 25:

Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression

http://ClinicalTrials.gov/show/NCT00868959

Study 26:

Lamictal as Add-on Treatment for Bipolar I Disorder in Pediatric Patients

http://ClinicalTrials.gov/show/NCT00723450

Study 27:

Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression

http://ClinicalTrials.gov/show/NCT01361555

Study 28:

A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder

http://ClinicalTrials.gov/show/NCT01173601

Study 29:

Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression

http://ClinicalTrials.gov/show/NCT01246908

Study 30:

A Study in Pediatric Patients With Generalized Anxiety Disorder

http://ClinicalTrials.gov/show/NCT01226511

Study 31:

Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)

http://ClinicalTrials.gov/show/NCT01312922

Study 32:

A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression

http://ClinicalTrials.gov/show/NCT01432236

Study 33:

Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder

http://ClinicalTrials.gov/show/NCT01364649

Study 34:

Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression

http://ClinicalTrials.gov/show/NCT01369095

Study 35:

A Study of LY2140023 in Patients With Schizophrenia

http://ClinicalTrials.gov/show/NCT01307800

Study 36:

A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)

http://ClinicalTrials.gov/show/NCT01500200

Study 37:

Safety and Efficacy of F2695 SR in Adults With Fatigue Associated With Major Depressive Disorder

http://ClinicalTrials.gov/show/NCT01254305

Study 38:

Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

http://ClinicalTrials.gov/show/NCT01305408

Study 39:

Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients

http://ClinicalTrials.gov/show/NCT00667810

Study 40:

A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder

http://ClinicalTrials.gov/show/NCT01482221

Study 41:

Effect of Different Doses of SAR110894D on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil

http://ClinicalTrials.gov/show/NCT01266525

Study 42:

Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

http://ClinicalTrials.gov/show/NCT01072630

Study 43:

Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder

http://ClinicalTrials.gov/show/NCT01163032

Study 44:

Efficacy and Safety Study of Low-Dose Ondansetron For Adjunctive Therapy In Adult Patients With Obsessive-Compulsive Disorder

http://ClinicalTrials.gov/show/NCT01275248

Study 45:

Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

http://ClinicalTrials.gov/show/NCT01436149

Study 46:

A Long-Term Study in Schizophrenia

http://ClinicalTrials.gov/show/NCT01487083

Study 47:

A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients

http://ClinicalTrials.gov/show/NCT01328093

Study 48:

Cariprazine Relative to Placebo in the Prevention of Relapse of Symptoms in Patients With Schizophrenia

http://ClinicalTrials.gov/show/NCT01412060

Study 49:

VI-1121 for the Treatment Alzheimer's Disease

http://ClinicalTrials.gov/show/NCT01428362

Study 50:

Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder

http://ClinicalTrials.gov/show/NCT01467700

Study 51:

A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment

http://ClinicalTrials.gov/show/NCT01187407

Study 52:

A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD

http://ClinicalTrials.gov/show/NCT01371708

Study 53:

Efficacy and Safety of Ramelteon Sublingual as Adjunctive Therapy for Maintenance Treatment of Bipolar I Disorder in Adult Patients

http://ClinicalTrials.gov/show/NCT01467713

Study 54:

Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception

http://ClinicalTrials.gov/show/NCT01429116

Study 55:

A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (NN25307)

http://ClinicalTrials.gov/show/NCT01235520

Study 56:

PEARL Schizophrenia Maintenance

http://ClinicalTrials.gov/show/NCT01435928

Study 57:

Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia

http://ClinicalTrials.gov/show/NCT01488929

Study 58:

A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

http://ClinicalTrials.gov/show/NCT01371734

Study 59:

A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor

http://ClinicalTrials.gov/show/NCT01185340

Study 60:

Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole

http://ClinicalTrials.gov/show/NCT01432444

Study 61:

Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression

http://ClinicalTrials.gov/show/NCT01309945

Study 62:

A Phase 1 Study of the Safety, Tolerability and Pharmacokinetics of ABT-126 in Subjects With Alzheimer's Disease

http://ClinicalTrials.gov/show/NCT01482845

Study 63:

Fixed Dose Efficacy and Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05896 AM2)

http://ClinicalTrials.gov/show/NCT01190254

Study 64:

Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder

http://ClinicalTrials.gov/show/NCT01430754

Study 65:

SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

http://ClinicalTrials.gov/show/NCT01435759

Study 66:

Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

http://ClinicalTrials.gov/show/NCT01436162

Study 67:

Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease

http://ClinicalTrials.gov/show/NCT00876863

Study 68:

Safety and Efficacy Study of IPX159 in Restless Legs Syndrome (RLS)

http://ClinicalTrials.gov/show/NCT01521663

Study 69:

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

http://ClinicalTrials.gov/show/NCT01343966

Study 70:

Flexible Dose, Long-term Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05897 AM2 EXT)

http://ClinicalTrials.gov/show/NCT01190267

Study 71:

A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)

http://ClinicalTrials.gov/show/NCT01192867

Study 72:

A Study in Prevention of Re-emergence of Depression Symptoms

http://ClinicalTrials.gov/show/NCT01299272

Study 73:

Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease

http://ClinicalTrials.gov/show/NCT01492374

Study 74:

ARTDeCo Study: A Study of RO4995819 in Patients With Major Depressive Disorder And Inadequate Response to Ongoing Antidepressant Treatment

http://ClinicalTrials.gov/show/NCT01457677

Study 75:

A Study of RO4917838 in Patients With Acute Exacerbation of Schizophrenia

http://ClinicalTrials.gov/show/NCT01234779

Study 76:

Phase 3 IGIV, 10% in Alzheimer´s Disease

http://ClinicalTrials.gov/show/NCT01524887

Study 77:

Ganaxolone in Posttraumatic Stress Disorder (PTSD)

http://ClinicalTrials.gov/show/NCT01339689

Study 78:

Safety and Efficacy of Rasagiline in Restless Legs Syndrome

http://ClinicalTrials.gov/show/NCT01192503

Study 79:

Cocaine Use Reduction With Buprenorphine

http://ClinicalTrials.gov/show/NCT01402492

Study 80:

A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease

http://ClinicalTrials.gov/show/NCT00235716

Study 81:

Study of Aripiprazole (Abilify) Versus Placebo in Children With Subsyndromal Bipolar Disorder

http://ClinicalTrials.gov/show/NCT00194012

Study 82:

Efficacy Study of Lisdexamfetamine to Treat Binge Eating Disorder

http://ClinicalTrials.gov/show/NCT01090713

Study 83:

Adjunctive Lisdexamfetamine (LDX) in Bipolar Depression

http://ClinicalTrials.gov/show/NCT01131559

Study 84:

Efficacy Study of Lisdexamfetamine to Treat Bipolar Depression

http://ClinicalTrials.gov/show/NCT01093963

Study 85:

Multisite Controlled Trial of Cocaine Vaccine

http://ClinicalTrials.gov/show/NCT00969878

Study 86:

Armodafinil in Binge Eating Disorder (BED)

http://ClinicalTrials.gov/show/NCT01010789

Stroke

(10 clinical trials recruiting)

Study 1:

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

http://ClinicalTrials.gov/show/NCT00856661

Study 2:

Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)

http://ClinicalTrials.gov/show/NCT00106938

Study 3:

Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3)

http://ClinicalTrials.gov/show/NCT01120301

Study 4:

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

http://ClinicalTrials.gov/show/NCT01225562

Study 5:

Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy

http://ClinicalTrials.gov/show/NCT01182441

Study 6:

Insulin Resistance Intervention After Stroke Trial

http://ClinicalTrials.gov/show/NCT00091949

Study 7:

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

http://ClinicalTrials.gov/show/NCT00968708

Study 8:

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

http://ClinicalTrials.gov/show/NCT01101035

Study 9:

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

http://ClinicalTrials.gov/show/NCT01327846

Study 10:

Aliskiren Effect on Plaque Progression In Established Atherosclerosis Using High Resolution 3D MRI (ALPINE)

http://ClinicalTrials.gov/show/NCT01417104

PhRMA

Pharmaceutical Research and Manufacturers of America
950 F Street, NW, Washington, DC 20004

www.phrma.org